Profile
| Metric | Value |
|---|---|
| Full Name | Alkermes plc |
| Ticker | NASDAQ: ALKS |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Specialty & Generic Drug Manufacturers |
| Country | Ireland |
| IPO | |
| Indexes | Not included |
| Website | alkermes.com |
| Employees | 1,800 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $28.00 | |
| Price, 1D Change | -0.92% | |
| Market Cap | $5B | |
| - | ||
| PE Ratio | 13.85 | |
| Beta | 0.59 | |
| Revenue | $2B | |
| Revenue, 1Y Change | -6.36% | |
| EPS | $2.17 | |
| EPS, 1Y Change | +3.51% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 2:1 | |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $2.17 | |
| EPS Estimate | $1.93 | |
| EPS Est. Change | -11.26% | |
| Revenue | $1.56B | |
| Revenue Estimate | $1.47B | |
| Revenue Est. Change | -5.65% | |
| Current Price | $28.00 | |
| Price Target | - | $45.00 |
| Price Tgt. Change | - | +60.71% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $1.67 | $2.10 | +25.51% | |
| $2.60 | $2.17 | -16.42% | |
| $1.93 | N/A | -11.26% | |
| $2.16 | N/A | -0.44% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $1.65B | $1.66B | +0.88% | |
| $1.51B | $1.56B | +3.40% | |
| $1.47B | N/A | -5.65% | |
| $1.80B | N/A | +15.86% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | -3.58% | |
| Price, 3Y | +10.63% | |
| Market Cap, 1Y | -1.83% | |
| Market Cap, 3Y | +11.13% | |
| Revenue, 1Y | -6.36% | |
| Revenue, 3Y | +32.71% | |
| EPS, 1Y | +3.51% | |
| EPS, 3Y | +824.86% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $28.00 | |
| SMA 200 | $29.47 | |
| SMA 200 vs Price | +5.24% | |
| SMA 50 | $29.47 | |
| SMA 50 vs Price | +5.24% | |
| Beta | 0.59 | |
| ATR | $0.83 | |
| 14-Day RSI | 42.59 | |
| 10-Day Volatility | 17.90% | |
| 1-Year Volatility | 35.08% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $1.56B | |
| EPS | $2.17 | |
| Gross Profit | $1.31B | |
| Gross Margin | 83.81% | |
| Operating Profit | $420.64M | |
| Operating Margin | 27.00% | |
| Net Income | $372.14M | |
| Net Margin | 23.89% | |
| EBITDA | $449.17M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.05 | |
| Current Ratio | 3.04 | |
| Quick Ratio | 2.65 | |
| - | ||
| F-Score | 7 | |
| Altman Z-Score | 6.02 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 13.85 | |
| PS Ratio | 3.04 | |
| PB Ratio | 2.67 | |
| EV/EBITDA | 9.22 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $1.46B | |
| Cash & Equivalents | $751.67M | |
| Total Assets | $2.06B | |
| Current Assets | $1.42B | |
| Total Liabilities | $590.59M | |
| Current Liabilities | $465.20M | |
| Total Debt | $75.54M | |
| Short Term Debt | $6.17M | |
| Accounts Payable | $45.63M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $1.19B | |
| Operating Expenses | $884.86M | |
| Cost Of Goods Sold | $252.13M | |
| SG&A | $0.00 | |
| D&A | $28.53M | |
| Interest Expense | $0.00 | |
| Income Tax | $71.61M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | $439.12M | |
| CFI | -$111.31M | |
| CFF | -$494.14M | |
| Capex | $33.48M | |
| Free Cash Flow | $405.64M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Truist Securities | → | |
| Wells Fargo | → | |
| Deutsche Bank | → | |
| Truist Securities | → | |
| Truist Securities | ||
| Wells Fargo | → | |
| Needham | → | |
| Mizuho | → | |
| RBC Capital | → | |
| Piper Sandler | → |
Analyst sentiment
Institutional ownership
Screeners with ALKS
Data Sources & References
- ALKS Official Website www.alkermes.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1520262/000119312525252524/0001193125-25-252524-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1520262/000095017025019011/0000950170-25-019011-index.htm
- ALKS Profile on Yahoo Finance finance.yahoo.com/quote/ALKS
- ALKS Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/alks
FAQ
What is the ticker symbol for Alkermes plc?
The ticker symbol for Alkermes plc is NASDAQ:ALKS
Does Alkermes plc pay dividends?
No, Alkermes plc does not pay dividends
What sector is Alkermes plc in?
Alkermes plc is in the Healthcare sector
What industry is Alkermes plc in?
Alkermes plc is in the Specialty & Generic Drug Manufacturers industry
What country is Alkermes plc based in?
Alkermes plc is headquartered in Ireland
When did Alkermes plc go public?
Alkermes plc initial public offering (IPO) was on July 16, 1991
Is Alkermes plc in the S&P 500?
No, Alkermes plc is not included in the S&P 500 index
Is Alkermes plc in the NASDAQ 100?
No, Alkermes plc is not included in the NASDAQ 100 index
Is Alkermes plc in the Dow Jones?
No, Alkermes plc is not included in the Dow Jones index
When was Alkermes plc last earnings report?
Alkermes plc's most recent earnings report was on October 28, 2025
When does Alkermes plc report earnings?
The next expected earnings date for Alkermes plc is February 11, 2026